Literature DB >> 2171466

An animal model for therapeutic intervention studies of CMV infection in the immunocompromised host.

F S Stals1, F Bosman, C P van Boven, C A Bruggeman.   

Abstract

An experimental rat model to study acute cytomegalovirus infections is described. Eight-week old male Brown Norway rats, immunosuppressed by total body irradiation, were infected with rat cytomegalovirus (RCMV). The effects of infection were determined by survival rates and the presence of virus or viral components in different organs was assayed by plaque test, immunoperoxidase staining, dot-blot DNA hybridization and in situ DNA hybridization. At days 10-post infection nearly 90% of the animals had died. Spleen, liver and bone marrow were heavily infected. Interstitial pneumonia was observed. Pathological findings strongly resembled the full scale of lesions in human CMV infections. Anti-RCMV hyperimmune serum was effective against mortality from RCMV infection and viral spread to lungs and liver was prevented. This model is appropriate for studies on the pathogenesis and antiviral therapy of CMV infections in the immunocompromised host.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171466     DOI: 10.1007/BF01311014

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  28 in total

1.  A PLAQUE REDUCTION NEUTRALIZATION TEST FOR HUMAN CYTOMEGALOVIRUS.

Authors:  G PLUMMER; M BENYESH-MELNICK
Journal:  Proc Soc Exp Biol Med       Date:  1964-10

2.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

Authors:  D R Snydman; B G Werner; B Heinze-Lacey; V P Berardi; N L Tilney; R L Kirkman; E L Milford; S I Cho; H L Bush; A S Levey
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

3.  Extraction of cellular DNA from human cells and tissues fixed in ethanol.

Authors:  L J Smith; R C Braylan; J E Nutkis; K B Edmundson; J R Downing; E K Wakeland
Journal:  Anal Biochem       Date:  1987-01       Impact factor: 3.365

4.  Antivirus antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection.

Authors:  J E Manischewitz; G V Quinnan
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  Passive transfer of cytomegalovirus by cardiac and renal organ transplants in a rat model.

Authors:  J H Bruning; C A Bruggeman; C P van Boven; P J van Breda Vriesman
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

6.  Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis.

Authors:  C A Wiley; J A Nelson
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

7.  The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients.

Authors:  M G Hendrix; P H Dormans; P Kitslaar; F Bosman; C A Bruggeman
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

8.  Cytomegalovirus hepatitis in normal and immune compromised hosts.

Authors:  C H Ten Napel; H J Houthoff; T H The
Journal:  Liver       Date:  1984-06

9.  Isolation of a cytomegalovirus-like agent from wild rats.

Authors:  C A Bruggeman; H Meijer; P H Dormans; W M Debie; G E Grauls; C P van Boven
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

10.  Cytomegaloviral infections in the guinea pig: experimental models for human disease.

Authors:  F J Bia; B P Griffith; C K Fong; G D Hsiung
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  13 in total

1.  The r144 major histocompatibility complex class I-like gene of rat cytomegalovirus is dispensable for both acute and long-term infection in the immunocompromised host.

Authors:  P S Beisser; J S Kloover; G E Grauls; M J Blok; C A Bruggeman; C Vink
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Structure of the rat cytomegalovirus genome termini.

Authors:  C Vink; E Beuken; C A Bruggeman
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  Deletion of the R78 G protein-coupled receptor gene from rat cytomegalovirus results in an attenuated, syncytium-inducing mutant strain.

Authors:  P S Beisser; G Grauls; C A Bruggeman; C Vink
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection.

Authors:  P S Beisser; C Vink; J G Van Dam; G Grauls; S J Vanherle; C A Bruggeman
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

6.  Triple drug immunosuppression significantly reduces immune activation and allograft arteriosclerosis in cytomegalovirus-infected rat aortic allografts and induces early latency of viral infection.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

7.  Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.

Authors:  F S Stals; A Zeytinoglu; M Havenith; E de Clercq; C A Bruggeman
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.

Authors:  B L Haagmans; F S Stals; P H van der Meide; C A Bruggeman; M C Horzinek; V E Schijns
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.

Authors:  B L Haagmans; P H van der Meide; F S Stals; A J van den Eertwegh; E Claassen; C A Bruggeman; M C Horzinek; V E Schijns
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.